Effects of Intrauterine Administration of Autologous PBMC Modulated With IFNt on Endometrial Cell Populations

ConditionInfertility
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexFemale
Age18-50
SponsorNadezhda Women's Health Hospital

About this trial

The aim of this clinical trial is to investigate the change in endometrial composition during the window of implantation following intrauterine administration of PBMC immunomodulated with IFNt.

Patients seeking assisted reproductive therapy will be invited to participate. Two endometrial biopsies will be obtained from each patient during mid-secretory phase of two consecutive menstrual cycles. The first biopsy will be obtained one month before the intervention, and the second one - a day after intrauterine administration of the tested cell treatment which will take place the following month.

Immunohistochemistry analysis of the cell composition of the endometrium will be performed.

Eligibility criteria

Qualifiers

Participating in Assisted Reproduction Treatment

Having primary infertility

Having regular menstrual cycles

Having signed informed consent

Disqualifiers

Uterine pathologies

Endometrial bacterial infections

Active endometrial inflammation

Polycystic ovary syndrome

Trial design

Treatments tested in this trial

  • Intrauterine administration of PBMC immunomodulated with IFNt

Treatment groups

300 Participants
are divided into 1 treatment group

Locations

1

Map coordinates are unavailable for these locations. Locations are shown below instead.

Nadezhda Women's Health HospitalRecruiting1330, Sofia, SofiaBulgariaBulgaria